Amicus Therapeutics (FOLD) Short Interest Ratio & Short Volume → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free FOLD Stock Alerts $10.71 -0.11 (-1.02%) (As of 04/23/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Amicus Therapeutics Short Interest DataCurrent Short Volume32,490,000 sharesPrevious Short Volume32,400,000 sharesChange Vs. Previous Month+0.28%Dollar Volume Sold Short$382.73 millionShort Interest Ratio / Days to Cover10.7Last Record DateMarch 31, 2024Outstanding Shares295,380,000 sharesPercentage of Shares Shorted11.00%Today's Trading Volume5,091,023 sharesAverage Trading Volume3,040,979 sharesToday's Volume Vs. Average167% Short Selling Amicus Therapeutics ? Sign up to receive the latest short interest report for Amicus Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatFOLD Short Interest Over TimeFOLD Days to Cover Over TimeFOLD Percentage of Float Shorted Over Time Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. Amicus Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202432,490,000 shares $382.73 million +0.3%N/A10.7 $11.78 3/15/202432,400,000 shares $371.95 million +4.8%N/A10.3 $11.48 2/29/202430,910,000 shares $396.27 million +15.4%N/A9.4 $12.82 2/15/202426,780,000 shares $374.92 million +9.8%N/A8.6 $14.00 1/31/202424,400,000 shares $303.29 million -2.6%N/A8.1 $12.43 1/15/202425,060,000 shares $330.29 million -2.7%N/A8.3 $13.18 Get the Latest News and Ratings for FOLD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/202325,750,000 shares $365.39 million -4.3%N/A8.8 $14.19 12/15/202326,910,000 shares $342.30 million +11.5%N/A9.2 $12.72 11/30/202324,140,000 shares $266.02 million +6.2%N/A9.6 $11.02 11/15/202322,730,000 shares $242.30 million +0.8%N/A9.6 $10.66 10/31/202322,560,000 shares $247.48 million +0.4%N/A10 $10.97 10/15/202322,480,000 shares $234.69 million +19.1%N/A9.3 $10.44 9/30/202318,870,000 shares $229.46 million -0.2%N/A7.9 $12.16 9/15/202318,900,000 shares $247.40 million -3.8%N/A8.6 $13.09 8/31/202319,640,000 shares $251.78 million +3.1%N/A8.5 $12.82 8/15/202319,050,000 shares $247.46 million -16.6%N/A7.9 $12.99 7/31/202322,830,000 shares $310.94 million +13.3%N/A8.2 $13.62 7/15/202320,150,000 shares $270.01 million -6.5%N/A7.9 $13.40 6/30/202321,540,000 shares $270.54 million +10.0%N/A8.7 $12.56 6/15/202319,580,000 shares $253.76 million +2.4%N/A7.6 $12.96 5/31/202319,120,000 shares $215.29 million -10.2%N/A7.6 $11.26 5/15/202321,300,000 shares $238.56 million -1.1%N/A8.7 $11.20 4/30/202321,530,000 shares $248.46 million +2.2%N/A9.8 $11.54 4/15/202321,060,000 shares $240.08 million +5.4%N/A9.9 $11.40 3/31/202319,980,000 shares $221.58 million -4.3%N/A8.9 $11.09 3/15/202320,880,000 shares $238.66 million +15.4%N/A9.8 $11.43 2/28/202318,090,000 shares $238.61 million +0.2%N/A8.6 $13.19 2/15/202318,060,000 shares $236.77 million -8.1%N/A8.8 $13.11 1/31/202319,650,000 shares $256.24 million +1.5%N/A9.3 $13.04 1/15/202319,370,000 shares $248.52 million -3.8%N/A8.5 $12.83 12/30/202220,140,000 shares $245.91 million +12.6%N/A9.2 $12.21 12/15/202217,880,000 shares $216.17 million -12.0%N/A7.8 $12.09 11/30/202220,310,000 shares $245.75 million +7.6%N/A8.3 $12.10 11/15/202218,880,000 shares $220.33 million +3.4%N/A7.4 $11.67 10/31/202218,260,000 shares $182.60 million -12.1%N/A7.1 $10.00 10/15/202220,780,000 shares $220.27 million +2.3%N/A7.8 $10.60 9/30/202220,310,000 shares $212.04 million -8.5%N/A7.3 $10.44 9/15/202222,200,000 shares $243.09 million +2.5%N/A7.4 $10.95 8/31/202221,660,000 shares $243.24 million +13.2%N/A6.9 $11.23 8/15/202219,130,000 shares $236.64 million -5.2%N/A5.8 $12.37Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. FOLD Short Interest - Frequently Asked Questions What is Amicus Therapeutics' current short interest? Short interest is the volume of Amicus Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 32,490,000 shares of FOLD short. Learn More on Amicus Therapeutics' current short interest. What is a good short interest ratio for Amicus Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FOLD shares currently have a short interest ratio of 11.0. Learn More on Amicus Therapeutics's short interest ratio. Which institutional investors are shorting Amicus Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Amicus Therapeutics: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Amicus Therapeutics' short interest increasing or decreasing? Amicus Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 32,490,000 shares, an increase of 0.3% from the previous total of 32,400,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Amicus Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Amicus Therapeutics: Alkermes plc (8.48%), Geron Co. (8.53%), BridgeBio Pharma, Inc. (10.29%), Madrigal Pharmaceuticals, Inc. (16.88%), Dynavax Technologies Co. (13.73%), Ligand Pharmaceuticals Incorporated (4.05%), Ironwood Pharmaceuticals, Inc. (14.48%), MannKind Co. (13.21%), Blueprint Medicines Co. (7.14%), Innoviva, Inc. (18.15%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Amicus Therapeutics stock? Short selling FOLD is an investing strategy that aims to generate trading profit from Amicus Therapeutics as its price is falling. FOLD shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Amicus Therapeutics? A short squeeze for Amicus Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of FOLD, which in turn drives the price of the stock up even further. How often is Amicus Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FOLD, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: Alkermes Short Interest Geron Short Interest BridgeBio Pharma Short Interest Madrigal Pharmaceuticals Short Interest Dynavax Technologies Short Interest Ligand Pharmaceuticals Short Interest Ironwood Pharmaceuticals Short Interest MannKind Short Interest Blueprint Medicines Short Interest Innoviva Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:FOLD) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals